Region: United States of America

Via Licensing taps Xiaomi’s former IP strategy head as advisor

Paul Lin, now managing director of Eagle Forest, aims to provide the licensee’s perspective to arm Via as it navigates a shifting patent pool landscape

23 March 2023

InterDigital’s UK setback highlights patent litigation risks

In retrospect, the US R&D and licensing business would surely have preferred to take a hit in order to settle its dispute with Lenovo out of sight and in secret

23 March 2023

Holistic IP strategy layering multiple forms of protection covers innovation at Waymo

In an exclusive interview, IP head Van Nguy reveals her rubric for building a foundational portfolio on emerging tech including a mix of patents, trade secrets and trade dress

22 March 2023

Examining the practice of Cedar Lane Technologies – America’s top-filing NPE

We talked with Greg Benoit, president of the Canadian company that filed the most cases in 2022, strongly favours the Western District of Texas, and has obtained a 96% settlement rate among its terminated cases

20 March 2023

We need a better debate about US pharma patents

Opinion: Popular attacks on America’s life sciences patent system are highly misleading

18 March 2023

Federal Circuit protects infringement demand letters as free speech

As long as an allegation is made in good faith – meaning not objectively baseless – the First Amendment protects a patent holder’s right to send them

17 March 2023

Moderna’s efforts to deflect covid vaccine infringement liability run into more difficulties

Surprise intervention of US government has not helped the mRNA company

17 March 2023

EDTX judge’s new limine order takes name-calling off the table

Chief Judge Rodney Gilstrap’s standing order, which bans terms like “patent troll” among other things, is expected to benefit clients by saving them money

16 March 2023

SVB’s collapse is a reminder of how far IP finance still has to travel

Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it

16 March 2023

Five things to watch in US Supreme Court oral argument in Amgen v Sanofi

Chief IP officers at large and small companies – especially life sciences – are closely watching the case which promises to settle debate about what comprises sufficient enablement under Section 112

15 March 2023

Unlock unlimited access to all IAM content